WATARU OKAMOTO

Last Updated :2024/04/03

Affiliations, Positions
Hiroshima University Hospital(Medical), Professor
E-mail
wokamotohiroshima-u.ac.jp

Basic Information

Major Professional Backgrounds

  • 2011/04, 2013/03, Kindai University, Medical Oncology, Assistant Professor
  • 2013/04, 2016/03, National Cancer Center, Hospital East, Staff
  • 2016/04, 2019/03, National Cancer Center, Hospital East, Chief
  • 2019/04, Hiroshima University, Hospital, Associate Professor

Educational Backgrounds

  • Ehime University, Japan, 1996/04, 2002/03
  • Kindai University, Japan, 2008/04, 2011/03

Academic Degrees

  • Ph.D., Kindai University

Educational Activity

Course in Charge

  1. 2024, Liberal Arts Education Program1, 1Term, Introductory Seminar for First-Year Students
  2. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Clinical Oncology
  3. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Clinical Oncology
  4. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Research on Clinical Oncology
  5. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Research on Clinical Oncology
  6. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Clinical Practice of Systemic Chemotherapy
  7. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Clinical Practice of Systemic Chemotherapy
  8. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Pediatric Cancer Treatment

Research Activities

Academic Papers

  1. The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine, Pathol Int., Online ahead of print., 202110
  2. SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors, Cancer Science, Online ahead of print., 202109
  3. Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice, CANCERS, 13(16), 202108
    Link to Paper Search Results by DOI
  4. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study, BMC GASTROENTEROLOGY, 21(1), 20210731
    Link to Paper Search Results by DOI
  5. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 40(1), 20210626
    Link to Paper Search Results by DOI
  6. Radical surgery for anal canal neuroendocrine carcinoma with pagetoid spread: a case report, JOURNAL OF SURGICAL CASE REPORTS, 202105
    Link to Paper Search Results by DOI
  7. An Autopsy Case of IGF‒II Secreting Gastric Cancer with Non‒Islet Cell Tumor Hypoglycemia, Gan To Kagaku Ryoho, 48(4), 523-525, 202104
  8. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab, CLINICAL JOURNAL OF GASTROENTEROLOGY, 14(1), 283-287, 202102
    Link to Paper Search Results by DOI
  9. FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer, CANCER SCIENCE, 112(1), 314-322, 202101
    Link to Paper Search Results by DOI
  10. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies, NATURE MEDICINE, 26(12), 202012
    Link to Paper Search Results by DOI
  11. Impact of DNA integrity on the success rate of tissue-based next-generation sequencing: Lessons from nationwide cancer genome screening project SCRUM-Japan GI-SCREEN, PATHOLOGY INTERNATIONAL, 70(12), 932-942, 202012
    Link to Paper Search Results by DOI
  12. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 25(3), 403-417, 202003
    Link to Paper Search Results by DOI
  13. ★, Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy., BMC cancer, 19(1), 255, 20190300
  14. Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study., Neoplasia (New York, N.Y.), 20(12), 1219-1226, 20181200
  15. Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer., Clinical colorectal cancer, 17(3), 198-205, 20180900
  16. Utility of the Quasi-monomorphic Variation Range in Unresectable Metastatic Colorectal Cancer Patients., Cancer science, 109(11), 3411-3415, 20180800
  17. Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study., Japanese journal of clinical oncology, 48(6), 559-564, 20180600
  18. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study., The Lancet Oncology, 18(9), 1172-1181, 20170900
  19. [Current Status and Future Perspectives of SCRUM-Japan]., Gan to kagaku ryoho. Cancer & chemotherapy, 44(8), 621-626, 20170800
  20. Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer., Clinical colorectal cancer, 16(2), e39-e44, 20170600
  21. Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib., Clinical colorectal cancer, 20161200
  22. Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials., BMC cancer, 16(1), 889, 20161100
  23. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution., Clinical colorectal cancer, 15(3), e109-15, 20160900
  24. A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors., Investigational new drugs, 33(5), 1058-1067, 20151000
  25. Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience., Investigational new drugs, 33(3), 664-670, 20150600
  26. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer., BMC cancer, 15, 258, 20150400
  27. Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study., EBioMedicine, 2(4), 317-323, 20150400
  28. Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer., Investigational new drugs, 32(5), 946-954, 20141000
  29. Targeting MET Amplification as a New Oncogenic Driver., Cancers, 6(3), 1540-1552, 20140700
  30. ★, A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors., Cancer chemotherapy and pharmacology, 72(5), 1063-1071, 20131100
  31. Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B., Breast cancer (Tokyo, Japan), 20(2), 131-136, 20130400
  32. MET amplification as a potential therapeutic target in gastric cancer., Oncotarget, 4(1), 9-17, 20130100
  33. Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer., Investigational new drugs, 30(4), 1511-1518, 20120800
  34. ★, Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification., Molecular cancer therapeutics, 11(7), 1557-1564, 20120700
  35. Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin., Anticancer research, 32(5), 1805-1809, 20120500
  36. Capecitabine plus Cisplatin treatment for advanced gastric cancer in a patient with hepatic impairment secondary to metastases., Gastrointestinal cancer research : GCR, 5(3), 103-105, 20120500
  37. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification., Oncogene, 30(39), 4097-4106, 20110900
  38. ★, Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells., British journal of cancer, 105(3), 407-412, 20110700
  39. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin., International journal of clinical oncology, 16(3), 244-249, 20110600
  40. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer., British journal of cancer, 104(10), 1594-1601, 20110500
  41. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations., Cancer research, 70(24), 10402-10410, 20101200
  42. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors., Molecular cancer therapeutics, 9(10), 2825-2833, 20101000
  43. ★, TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation., Molecular cancer therapeutics, 9(10), 2785-2792, 20101000
  44. ★, Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition., Molecular cancer therapeutics, 9(5), 1188-1197, 20100500
  45. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification., Cancer science, 101(1), 167-172, 20100100

Invited Lecture, Oral Presentation, Poster Presentation

  1. Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602)., Okamoto W, Nakamura Y, Kato T, Esaki T, Komoda M, Kato K, Komatsu Y, Masuishi T, Nishina T, Sawada K, Taniguchi H, Fuse N, Nomura S, Fukui M, Olsen S, Odegaard J, Sato A, Fujii S, Ohtsu A, Yoshino T, ASCO Annual Meeting 2021, 2021/06, Without Invitation, English, American Society of Clinical Oncology
  2. Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer, Okamoto W, Nakamura Y, Shiozawa M, Komatsu Y, Denda T, Hara H, Kagawa Y, Narita Y, Kawakami H, Esaki T, Nishina T, Izawa N, Ando K, Moriwaki T, Kato T, Nagashima F, Satoh T, Nomura S, Yoshino T, Akagi K, ESMO Congress 2019, 2019/09/29, Without Invitation, English, European Society for Medical Oncology, Barcelona, Spain
  3. TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study, Nakamura Y, Okamoto W, Kato T, Hasegawa H, Kato K, Iwasa S, Esaki T, Komatsu Y, Masuishi T, Nishina T, Nomura S, Fukui M, Matsuda S, Sato A, Fujii S, Odegaard J, Olsen S, Yoshino T, ESMO Congress 2019, 2019/09/29, Without Invitation, English, European Society for Medical Oncology Cancer, Barcelona, Spain
  4. Prognostic and predictive impact on FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer, Hasegawa H, Taniguchi H, Kato T, Fujii S, Ebi H, Shiozawa M, Yuki S, Masuishi T, Kato K, Izawa N, Moriwaki T, Kagawa Y, Sakamoto Y, Okamoto W, Nakamura Y, Yamazaki K, Yoshino T, ESMO Congress 2019, 2019/09/29, Without Invitation, English, European Society for Medical Oncology Cancer, Barcelona, Spain
  5. ctDNA mutations correlate with efficacy of mFOLFOX6/XELOX plus bevacizumab in mCRC patients (WJOG7612GTR), Sakai K, Okamoto W, Okamura S, Yasui H, Miyamoto Y, Sugimoto N, Funakoshi S, Sato M, Miyata Y, Tamura T, Kotaka M, Shinozaki K, Makiyama A, Boku N, Hyodo I, Yamazaki K, Hironaka S, Yamanaka T, Muro K, Nishio K, JSMO2019, 2019/07/20, Without Invitation, English, Japanese Society of Medical Oncology, Kyoto, Japan
  6. Data standardization for Regulatory-grade Real World Data - Initiatives in the SCRUM-Japan Registry, Okamoto W, Aoyagi Y, Sakamoto Y, Ohtsu A, JSMO2019, 2019/07/19, Without Invitation, English, Japanese Society of Medical Oncology, Kyoto, Japan
  7. Therapeutic development for HER2 positive metastatic colorectal cancer, Okamoto W, Nakamura Y, Yoshino T, JSMO2019, 2019/07/18, With Invitation, English, Japanese Society of Medical Oncology, Kyoto, Japan
  8. Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: Combined tissue and blood-based analysis from SCRUM-Japan GI-SCREEN and GOZILA, Nakamura Y, Yamashita R, Okamoto W, Narita Y, Komatsu Y, Kagawa Y, Takahashi N, Esaki T, Kato T, Sunakawa Y, Denda T, Nishina T, Takashima A, Kobayashi T, Shiozawa M, Oki E, Satoh T, Adachi Y, Odegaard J, Yoshino T, ASCO Annual Meeting 2019, 2019/06/03, Without Invitation, English, American Society of Clinical Oncology, Chicago, US
  9. Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN, Mizukami T, Takahashi M, Sunakawa Y, Yuki S, Kagawa Y, Takashima A, Kato K, Hara H, Denda T, Moriwaki T, Shiozawa M, Oki E, Satoh T, Kawakami H, Esaki T, Nishina T, Okamoto W, Yoshino T, Nakajima E T, Gastrointestinal Cancers Symposium 2019, 2019/01/19, Without Invitation, English, American Society of Clinical Oncology, San Francisco, US
  10. Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN, Nakamura Y, Okamoto W, Shitara K, Kojima T, Morizane C, Naito Y, Yuki S, Kagawa Y, Narita Y, Nakashima Y, Takahashi H, Ueno M, Kato K, Komatsu Y, Ohtsu A, Akagi K, Yoshino T, ASCO Annual Meeting 2018, 2018/06/04, Without Invitation, English, American Society of Clinical Oncology, Chicago, US
  11. The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC), Yuki S, Shitara K, Kadowaki S, Minashi K, Takeno A, Hara H, Kajiwara T, Sunakawa Y, Iwasa S, Yamamoto Y, Nagashima F, Nakanishi R, Esaki T, Yoshikawa T, Nomura S, Kuwata T, Fujii S, Okamoto W, Ohtsu A, Yoshino T, ASCO Annual Meeting 2018, 2018/06/03, Without Invitation, English, American Society of Clinical Oncology, Chicago, US
  12. International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method, Fujii S, Magliocco M A, Valtorta E, Kim J, Okamoto W, Kim E J, Sawada K, Nakamura Y, Torri V, Kopetz S, Park Y W, Tsuchihara K, Kim W T, Raghav S KP, Siena S, Yoshino T, ASCO Annual Meeting 2018, 2018/06/03, Without Invitation, English, American Society of Clinical Oncology, Chicago, US
  13. Plasma VEGF-A (pVEGF-A) level in efficacy analysis of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR), Okamoto W, Makiyama A, Yamamoto Y, Shitara K, Denda T, Izawa N, Nakano Y, Nishina T, Esaki T, Hara H, Ozaki Y, Okuda H, Boku N, Hyodo I, Yamazaki K, Hironaka S, Sakai K, Yamanaka T, Muro K, Nishio K, Gastrointestinal Cancers Symposium 2018, 2018/01/20, Without Invitation, English, American Society of Clinical Oncology, San Francisco, US
  14. Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR), Yamamoto Y, Okamoto W, Makiyama A, Shitara K, Denda T, Ogura T, Nakano Y, Nishina T, Komoda M, Hara H, Ozaki Y, Kawakami H, Boku N, Hyodo I, Yamazaki K, Hironaka S, Sakai K, Yamanaka T, Muro K, Nishio K, Gastrointestinal Cancers Symposium 2018, 2018/01/20, Without Invitation, English, American Society of Clinical Oncology, San Francisco, US
  15. Survival outcome in HER2-amplified metastatic colorectal cancer (mCRC), Sawada K, Okamoto W, Nakamura Y, Yamanaka T, Yuki S, Yoshino T, Komatsu Y, Sakamoto N, Fujii S, Gastrointestinal Cancers Symposium 2018, 2018/01/20, Without Invitation, English, American Society of Clinical Oncology, San Francisco, US
  16. Clinical utility of quasimonomorphic variation range (QMVR) on the determination of microsatellite instability (MSI) status in Japanese patients (pts) with colorectal cancer (CRC): GI-SCREEN-CRC-MSI sub-study 01, Bando H, Okamoto W, Fukui T, Yamanaka T, Akagi K, Yoshino T, Gastrointestinal Cancers Symposium 2017, 2017/01/21, Without Invitation, English, American Society of Clinical Oncology, San Francisco, US
  17. A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410, Kuboki Y, Nishina T, Yamaguchi K, Shinozaki E, Komatsu Y, Yuki S, Yamazaki K, Hara H, Fukutani M, Uchida Y, Tsukahara N, Hasegawa H, Matsuda S, Okamoto W, Yonemura M, Nomura S, Sato A, Ohtsu A, Yoshino T, ASCO Annual Meeting 2016, 2016/06/04, Without Invitation, English, American Society of Clinical Oncology, Chicago, US
  18. The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced non-colorectal (Non-CRC) gastrointestinal cancer, Takashima A, Okamoto W, Hironaka S, Kato T, Komatsu Y, Kajiwara T, Izawa N, Esaki T, Hara H, Nakanishi R, Yamamoto Y, Ebi H, Kadowaki S, Kuwata T, Fujii S, Doi T, Ohtsu A, Shitara K, Yoshino T, ASCO Annual Meeting 2016, 2016/06/04, Without Invitation, English, American Society of Clinical Oncology, Chicago, US
  19. The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer, Kato T, Okamoto W, Hamaguchi T, Hara H, Taniguchi H, Mizukami T, Denda T, Moriwaki T, Esaki T, Yuki S, Oki E, Kajiwara T, Kudo T, Naruge D, Tamura T, Fujii S, Doi T, Ohtsu A, Shitara K, Yoshino T, ASCO Annual Meeting 2016, 2016/06/04, Without Invitation, English, American Society of Clinical Oncology, Chicago, US
  20. Clinicopathological features of microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in Japanese patients, Kawazoe A, Shitara K, Noguchi M, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T, Gastrointestinal Cancers Symposium 2016, 2016/01/23, Without Invitation, English, American Society of Clinical Oncology, San Francisco, US
  21. The Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan (SCRUM-Japan GI-SCREEN): Efficient identification of actionable cancer genome alterations in advanced colorectal and non-colorectal gastrointestinal cancer (GI Screen 2013-01-CRC and 2015-01-Non CRC), Shitara K, Miki I, Sudo T, Fujii S, Kuwata T, Okamoto W, Denda T, Kajiwara T, Yuki S, Nakajima E T, Takashima A, Kawasaki K, Tamura T, Esaki T, Yamanaka T, Ochiai A, Doi T, Ohtsu A, Hotta T, Yoshino T, ASCO Annual Meeting 2015, 2015/06/01, Without Invitation, English, American Society of Clinical Oncology, Chicago, US
  22. An investigator initiated multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE), Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, Kajiwara T, Matsumoto T, Tsushima T, Mochizuki N, Fukutani M, Nakamoto M, Hasegawa H, Sugama A, Nomura S, Sato A, Ohtsu A, Yoshino T, ASCO Annual Meeting 2015, 2015/06/01, Without Invitation, English, American Society of Clinical Oncology, Chicago, US
  23. Prophylactic use of oral dexamethasone (DEX) to alleviate fatigue during regorafenib (REG) treatment for patients with advanced colorectal cancer (aCRC), Fukuoka S, Shitara K, Noguchi M, Kawazoe A, Kuboki Y, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T, Gastrointestinal Cancers Symposium 2015, 2015/01/17, Without Invitation, English, American Society of Clinical Oncology, San Francisco, US
  24. Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: The NCCHE experience, Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Yoshino T, Doi T, Ohtsu A, Gastrointestinal Cancers Symposium 2015, 2015/01/15, Without Invitation, English, American Society of Clinical Oncology, San Francisco, US
  25. A phase ll study of new combination regimen with trastuzumab, S-1, and CDDP in HER2-positive advanced gastric cancer (HERBIS-1), Koeda K, Sugimoto N, Tanaka J, Tsuda M, Okamoto W, Okuda H, Imamura H, Matsuyama J, Shimokawa S, Sakai D, Fukushima N, Kurokawa Y, Komatsu Y, Tsujinaka T, Furukawa H, ASCO Annual Meeting 2013, 2013/06/02, Without Invitation, English, American Society of Clinical Oncology, Chicago, US
  26. A phase ll study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer (HERBIS-1), Sugimoto N, Tanaka J, Tsuda M, Okamoto W, Okuda H, Imamura H, Shimokawa T, Sakai D, Kurokawa Y, Komatsu Y, Ishioka C, Tsujinaka T, Takiuchi H, Furukawa H, Gastrointestinal Cancers Symposium 2013, 2013/01/24, Without Invitation, English, American Society of Clinical Oncology, San Francisco, US